Abstract P259 – Table 1. Logistic regression analysis to assess the relationship between sociodemographic, clinical variables, and disease progression in 1118 patients infected by SARS‐CoV‐2.
Variables	Univariate	Analysis	Multivariate	Analysis
	OR (95% CI)	p‐value	OR (95% CI)	p‐value
Age	1.03 (1.02 to 1.04)	<0.0001	1.04 (1.02 to 1.05)	<0.0001
Males	1.10 (0.86 to 1.42)	0.44	−	−
BMI >30 kg/m2	1.24 (0.93 to 1.66)	0.14	−	−
CKD	1.24 (0.88 to 1.76)	0.22	−	−
Immunodeficiency	0.89 (0.64 to 1.26)	0.53	−	−
Decompensated diabetes	1.61 (1.11 to 2.33)	0.01	1.03 (0.59 to 1.81)	0.91
Chronic liver disease	1.40 (0.86 to 2.28)	0.17	−	−
Chronic respiratory disease	1.69 (1.24 to 2.28)	0.001	1.73 (1.11 to 2.69)	0.02
Neurological disorders	1.52 (1.12 to 2.05)	0.006	1.42 (0.93 to 2.16)	0.10
Oncological disease	0.72 (0.51 to 1.02)	0.06	−	−
Haematological tumours	1.61 (0.99 to 2.63)	0.06	2.82 (1.41 to 5.65)	0.003
Cardiovascular diseases	1.22 (0.95 to 1.58)	0.12	−	−
Number of comorbidities	1.20 (1.09 to 1.31)	<0.0001	−	−
CCI	1.09 (1.04 to 1.14)	<0.001	−	−
4C‐score	1.36 (1.29 to 1.43)	<0.0001	−	−
Vaccine (at least two doses)	0.18 (0.13 to 0.24)	<0.0001	0.22 (0.15 to 0.33)	<0.0001
At least one symptom	3.80 (2.34 to 6.19)	<0.0001	−	−
Fever	1.92 (1.49 to 2.47)	<0.0001	2.20 (1.53 to 3.15)	<0.0001
Dyspnoea	16.49 (11.95 to 22.76)	<0.0001	13.24 (8.99 to 19.50)	<0.0001
Any antiviral	0.11 (0.08 to 0.16)	<0.0001	−	−
Molnupiravir	0.14 (0.09 to 0.21)	<0.0001	0.13 (0.08 to 0.21)	<0.0001
Nirmatrelvir/ritonavir	−	−	−	−
Remdesivir	0.36 (0.15 to 0.86)	0.02	0.18 (0.06 to 0.52)	0.002
Any monoclonal antibodies	0.35 (0.24 to 0.52)	<0.0001	−	−
Sotrovimab	0.27 (0.14 to 0.52)	<0.0001	0.37 (0.16 to 0.84)	0.02
Casirivimab/imdevimab	0.49 (0.32 to 0.75)	<0.0001	0.50 (0.28 to 0.89)	0.02